

2011 FEB 11 A 10:47

February 10, 2011

Claudia Lewis-Eng

T 202.344.4359

F 202.344.8300

CLewis-Eng@venable.com

**VIA ELECTRONIC FILING (www.regulations.gov)
AND UPS NEXT DAY AIR**

Division of Dockets Management
HFA-305
Food and Drug Administration
5630 Fishers Lane, Rm. 1061
Rockville, MD 20852

**Re: Request for Extension of Time to Comment
Docket Nos. FDA-2000-P-0102, FDA-2000-P-0133, and FDA-2006-P-0033**

Dear Madam/Sir:

We write to request an extension of the comment period regarding the U.S. Food and Drug Administration's ("FDA") recent proposed rule that: (1) would amend 21 C.F.R. § 101.83, which governs health claims and phytosterols, and (2) indicated FDA's intention to abandon its enforcement discretion based on its 2003 Letter of Enforcement Discretion ("2003 Letter").¹

In particular, under the proposed rule, only dietary supplements containing esterified phytosterols are eligible for the health claim, which is a significant departure from the agency's position in its 2003 Letter. FDA invited public submission of additional data that demonstrate the cholesterol-lowering efficacy of nonesterified, or free, phytosterols consumed as ingredients in dietary supplements, and stated that the agency would consider additional information before making a final determination on this issue. FDA also requested data to provide a justification for inclusion/exclusion of a specific dietary supplement formulation using USP standards.

Presently, the comment period is scheduled to end on February 22, 2011. We respectfully request that this period be extended sixty (60) days, or until April 23, 2011, to ensure that all interested parties have sufficient time to submit the information and data requested by the agency.

As FDA notes, the proposed rule would prohibit marketers of dietary supplement products containing free phytosterols from making coronary heart disease health claims, which would have a significant adverse impact on numerous manufacturers who produce these products. In addition, removing these products from the marketplace without sufficient scientific justification

¹ 75 Fed. Reg. 76,526 (Dec. 8, 2010).

EXT

FDA Division of Dockets Management
February 10, 2011
Page 2 of 2

comprehensive assessment prepared by independent experts with relevant expertise in the field. Extending the comment period would allow interested members of the public, patients, clinicians and businesses the time necessary to provide the agency with a thorough review of available materials and information on this important issue.

Given the substantial impact upon all of these interested parties and consumers, we respectfully request that FDA extend the date by which comments are due until April 23, 2011.

Respectfully,

A handwritten signature in black ink, appearing to read "Michelle C. Jackson". The signature is fluid and cursive, with the last name "Jackson" being more prominent.

Claudia A. Lewis-Eng
Michelle C. Jackson
Seung-Hyun Ryu


MICHELLE C. JACKSON
(202) 344-4492
DC
575 7TH ST NW
WASHINGTON DC 20004

LTR


1 OF 1

SHIP TO:

DIVISION OF DOCKETS MANAGEMENT
FOOD AND DRUG ADMINISTRATION
ROOM 1061
5630 FISHERS LANE
HFA-305
ROCKVILLE MD 20852




MD 207 9-78



UPS NEXT DAY AIR

TRACKING #: 1Z E20 847 01 5522 6043

1



BILLING: P/P

CLIENT MATTER: 117207283368
USER ID: 2463

WS 11.0.15

LP2644 12.0A 01/2011



SEE NOTICE ON REVERSE regarding UPS Terms, and notice of limitation of liability. Where allowed by law, shipper authorizes UPS to act as forwarding agent for export control and customs purposes. If exported from the US, shipper certifies that the commodities, technology or software were exported from the US in accordance with the Export Administration Regulations. Diversion contrary to law is prohibited.